Zuellig Pharma Malaysia has entered into a distribution agreement with Taiho Pharma Singapore for their latest product, the TS-ONE OD Tablet.

The TS-ONE OD Tablet is the world's first anticancer agent in orally disintegrating tablet form that was developed to meet the needs of patients who have difficulty swallowing capsules or whose water intake is being restricted.

“We are excited to work with Taiho Pharma Singapore to bring such an innovative drug to the Malaysian market. We have been working closely with them for the past year and we hope to continue our partnership with them in the years to come,” said Robert Kruit, Chief Executive Zuellig Pharma Malaysia.